Royalty Rates. As further consideration for the rights granted to Licensee hereunder, commencing upon the First Commercial Sale of a Licensed Product in the Territory, Licensee shall pay to AstraZeneca a royalty on Net Sales with respect to each Licensed Product in each country in the Territory on a Licensed Product-by-Licensed Product and country-by-country basis during each Calendar Year at the following rates:
Appears in 4 contracts
Samples: Confidential Treatment (Biohaven Pharmaceutical Holding Co Ltd.), License Agreement (Biohaven Research Ltd.), License Agreement (Biohaven Pharmaceutical Holding Co Ltd.)
Royalty Rates. As further consideration for the rights granted to Licensee hereunder, commencing upon the First Commercial Sale of a Licensed Product in the Territory, Licensee shall pay to AstraZeneca a royalty on Net Sales with respect to each Licensed Product in each country in the Territory on a Licensed Product-by-Licensed Product and country-by-country basis basis, Licensee shall pay to AstraZeneca during the Royalty Term a royalty on Net Sales of each Licensed Product in the Territory during each Calendar Year at the following rates:
Appears in 2 contracts
Samples: License Agreement (Dermavant Sciences LTD), License Agreement (Dermavant Sciences LTD)
Royalty Rates. As further consideration for the rights granted to Licensee hereunder, commencing upon the First Commercial Sale of a Licensed Product in the Territory, Licensee shall pay to AstraZeneca a royalty AstraZeneca, during the Royalty Term, [***] on aggregate Net Sales with respect to each of all Licensed Product in each country Products in the Territory on a Licensed Product-by-Licensed Product and country-by-country basis during each Calendar Year at the following rates:Year.
Appears in 2 contracts
Samples: License Agreement (Arcutis Biotherapeutics, Inc.), License Agreement (Arcutis Biotherapeutics, Inc.)
